SG11201809669RA - Use of glutamate modulating agents with immunotherapies to treat cancer - Google Patents

Use of glutamate modulating agents with immunotherapies to treat cancer

Info

Publication number
SG11201809669RA
SG11201809669RA SG11201809669RA SG11201809669RA SG11201809669RA SG 11201809669R A SG11201809669R A SG 11201809669RA SG 11201809669R A SG11201809669R A SG 11201809669RA SG 11201809669R A SG11201809669R A SG 11201809669RA SG 11201809669R A SG11201809669R A SG 11201809669RA
Authority
SG
Singapore
Prior art keywords
international
rule
bhv
applicant
pct
Prior art date
Application number
SG11201809669RA
Inventor
Vladimir Coric
Original Assignee
Biohaven Pharm Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharm Holding Co Ltd filed Critical Biohaven Pharm Holding Co Ltd
Publication of SG11201809669RA publication Critical patent/SG11201809669RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

20 40 60 8 0 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 November 2017 (23.11.2017) WIPO I PCT omit VIII mum o 100 1101 Imo oimIE (10) International Publication Number WO 2017/201502 Al W O 20 17 / 20 15 0 2 Al (51) International Patent Classification: A61K 31/428 (2006.01) CO7D 277/82 (2006.01) (21) International Application Number: PCT/US2017/033690 (22) International Filing Date: 19 May 2017 (19.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/339,433 20 May 2016 (20.05.2016) US (71) Applicant: BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. [US/US]; 234 Church Street, Suite 301, New Haven, Connecticut 06520 (US). (72) Inventor: CORIC, Vladimir; 234 Church Street, Suite 301, New Haven, Connecticut 06520 (US). (74) Agent: VOLLES, Warren, K. et al.; IPRAXUS LEGAL, LLC, P.O. Box 689, 67 Sterling Hill Road, Old Lyme, Con- necticut 06371 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = (54) Title: USE OF GLUTAMATE MODULATING AGENTS WITH IMMUNOTHERAPIES TO TREAT CANCER Figure Co n trol P D - 1 B HV -1 5 \" 61 B H V -3 0 B H V-45 PD -1 +BHV- 1 5 P D-1+BHV-3 0 PD-1+BHV -4 5 Days after Implantation (57) : Disclosed are methods of treating cancer using a combination of an immunotherapeutic agent, such as, for example, a PD-1, PD-L1 or CTLA-4 checkpoint inhibitor, and a glutamate modulating agent such as riluzole or trigriluzole. Pharmaceutical compositions and kits including the immunotherapeutic agents and glutamate modulating agents are also disclosed. [Continued on next page] WO 2017/201502 Al O II Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201809669RA 2016-05-20 2017-05-19 Use of glutamate modulating agents with immunotherapies to treat cancer SG11201809669RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662339433P 2016-05-20 2016-05-20
PCT/US2017/033690 WO2017201502A1 (en) 2016-05-20 2017-05-19 Use of glutamate modulating agents with immunotherapies to treat cancer

Publications (1)

Publication Number Publication Date
SG11201809669RA true SG11201809669RA (en) 2018-11-29

Family

ID=60326148

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809669RA SG11201809669RA (en) 2016-05-20 2017-05-19 Use of glutamate modulating agents with immunotherapies to treat cancer

Country Status (25)

Country Link
US (3) US11400155B2 (en)
EP (3) EP4019019B1 (en)
JP (4) JP7224186B2 (en)
KR (2) KR102525527B1 (en)
CN (2) CN115350263A (en)
AU (2) AU2017266951B2 (en)
BR (1) BR112018073781A2 (en)
CA (1) CA3025019A1 (en)
CY (1) CY1124999T1 (en)
DK (1) DK3458053T3 (en)
EA (1) EA201892587A1 (en)
ES (2) ES2912131T3 (en)
HR (1) HRP20220237T1 (en)
HU (1) HUE058184T2 (en)
IL (2) IL292302B2 (en)
LT (1) LT3458053T (en)
MX (2) MX2018013868A (en)
PH (1) PH12018502409A1 (en)
PL (1) PL3458053T3 (en)
PT (1) PT3458053T (en)
RS (1) RS62935B1 (en)
SG (1) SG11201809669RA (en)
SI (1) SI3458053T1 (en)
WO (2) WO2017201502A1 (en)
ZA (1) ZA201807398B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138753A1 (en) * 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
JP6700293B2 (en) * 2015-03-03 2020-05-27 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． Riluzole prodrugs and their use
MA44594B1 (en) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anti-ctla-4 Antibodies and Methods of Use thereof
EA201890285A1 (en) 2015-07-13 2018-08-31 Сайтомкс Терапьютикс, Инк. ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION
CN108601767A (en) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 With the combination treatment of glutamine enzyme inhibitor and immune oncology medicament
RS62935B1 (en) * 2016-05-20 2022-03-31 Biohaven Therapeutics Ltd Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
BR112019011651A2 (en) 2016-12-07 2020-01-07 Agenus Inc. ANTI-CTTLA-4 ANTIBODIES AND METHODS OF USE OF THE SAME
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
EP3703822A4 (en) * 2017-11-03 2021-11-10 Calithera Biosciences, Inc. Conjoint therapy with glutaminase inhibitors
KR20200138714A (en) 2018-02-21 2020-12-10 에이아이 테라퓨틱스, 인코포레이티드 Combination therapy with apilimod and glutamate agents
CN111971308A (en) 2018-03-02 2020-11-20 戊瑞治疗有限公司 B7-H4 antibodies and methods of use thereof
KR20210034621A (en) * 2018-07-22 2021-03-30 바이오하벤 테라퓨틱스 리미티드 Uses of riluzole prodrugs for the treatment of Alzheimer's disease
EP3914266A4 (en) * 2019-01-24 2022-12-07 University of Cincinnati Autologous tumor organoid and immune cell co-cultures and methods of use as predictive models for pancreatic cancer treatment
WO2020252353A1 (en) * 2019-06-12 2020-12-17 Vanderbilt University Amino acid transport inhibitors and the uses thereof
CN110646557A (en) * 2019-10-12 2020-01-03 北京航空航天大学 Urine metabolic marker of glioblastoma patient carrying IDH gene mutation and application thereof
JP7431412B2 (en) 2019-12-23 2024-02-15 三菱マテリアル株式会社 How to separate covered wires
JP2023518218A (en) * 2020-03-17 2023-04-28 オハイオ・ステイト・イノベーション・ファウンデーション Designer extracellular vesicles for treating excitotoxicity
KR102441650B1 (en) * 2020-07-31 2022-09-08 서울대학교병원 Method for providing effective dose information on anticancer medicine in multidrug chemotherapy
WO2022197767A1 (en) * 2021-03-17 2022-09-22 Memorial Sloan-Kettering Cancer Center Methods for improving survival in lung cancer patients via ketamine oncoprotection
TW202320782A (en) * 2021-07-21 2023-06-01 美商維拉克塔股份有限公司 Cancer treatment combinations
WO2023202652A1 (en) * 2022-04-21 2023-10-26 Jacobio Pharmaceuticals Co., Ltd. Pharmaceutical combination and use thereof
CN116492322A (en) * 2023-05-10 2023-07-28 徐州医科大学 Application of small molecule blocker MEM in preparation of tumor treatment drugs

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US135A (en) 1837-03-03 Jesse j
CA209066A (en) 1921-03-01 Tschirner Frederick Conversion of potassium to soluble state
US7812A (en) 1850-12-03 Nail-plate feeder and turner
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
EP0804170B1 (en) 1993-07-09 2001-11-14 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998016249A1 (en) 1996-10-11 1998-04-23 Bristol-Myers Squibb Company Methods and compositions for immunomodulation
CA2281473C (en) 1997-02-20 2007-01-16 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
AU743758B2 (en) 1997-04-07 2002-02-07 Genentech Inc. Anti-VEGF antibodies
DK1001748T3 (en) 1997-07-25 2006-08-21 Alpex Pharma Sa Process for the preparation of a granule suitable for the preparation of tablets which can be dissolved in the mouth which can be rapidly decomposed
CA2349203C (en) 1998-11-20 2013-05-21 Rtp Pharma Inc. Dispersible phospholipid stabilized microparticles
EE05627B1 (en) 1998-12-23 2013-02-15 Pfizer Inc. Human monoclonal antibodies to CTLA-4
JP4780633B2 (en) 1999-06-25 2011-09-28 イムノゲン インコーポレーティッド Method of treatment using anti-ErbB antibody-maytansinoid complex
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CN1371416B (en) 1999-08-24 2012-10-10 梅达里克斯公司 Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
CA2463495C (en) 2001-10-12 2011-05-24 Elan Pharma International Ltd. Compositions having a combination of immediate release and controlled release characteristics
CA2476250C (en) 2002-02-13 2010-08-03 Michael K. Weibel Drug dose-form and method of manufacture
JP2005526506A (en) 2002-03-04 2005-09-08 イムクローン システムズ インコーポレイティド KDR specific human antibody and use thereof
EP1539237A4 (en) 2002-07-30 2006-05-24 Bristol Myers Squibb Co Humanized antibodies against human 4-1bb
DK1673397T3 (en) 2003-07-02 2011-03-07 Univ Genova Method for Preparation and Evaluation of Cytotoxicity of KIR2DL NK Receptors Antibodies
EP2292264A3 (en) 2003-07-24 2012-12-19 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
JP5112863B2 (en) 2004-07-01 2013-01-09 ノヴォ ノルディスク アー／エス Human anti-KIR antibody
PT1786785E (en) 2004-08-26 2010-05-21 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
CA2577937C (en) 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
EP2377555A3 (en) 2004-11-18 2011-11-23 Imclone LLC Antibodies against vascular endothelial growth factor receptor-1
EP1835929B8 (en) 2005-01-06 2016-07-27 Novo Nordisk A/S Anti-kir combination treatments and methods
SI1836225T1 (en) 2005-01-06 2012-06-29 Novo Nordisk As Kir-binding agents and methods of use thereof
PT2343320T (en) 2005-03-25 2018-01-23 Gitr Inc Anti-gitr antibodies and uses thereof
KR101498834B1 (en) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1744020A1 (en) 2005-07-14 2007-01-17 Siemens Aktiengesellschaft Method for starting a steam turbine plant
AU2006301163B2 (en) 2005-10-14 2012-02-23 Innate Pharma Compositions and methods for treating proliferative disorders
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AU2006323027B2 (en) 2005-12-05 2012-08-02 Pfizer Products Inc Method of treating abnormal cell growth
RU2387650C2 (en) 2005-12-05 2010-04-27 Пфайзер Продактс Инк. C-met/hgfr inhibitor polymorphs
WO2007074472A2 (en) 2005-12-27 2007-07-05 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
SI2526934T1 (en) 2006-09-22 2016-04-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN105037549B (en) 2007-01-11 2018-09-28 诺和诺德公司 Anti-KIR antibodies, preparation and its application
JP2008278814A (en) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk Release of immunoregulation by agonistic anti-human gitr antibody, and application thereof
DK2170959T3 (en) 2007-06-18 2014-01-13 Merck Sharp & Dohme ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1
EP2170282A4 (en) 2007-06-27 2014-11-05 Hanmi Pharm Ind Co Ltd Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same
CN101801413A (en) 2007-07-12 2010-08-11 托勒克斯股份有限公司 Combination therapies employing GITR binding molecules
PL2195017T3 (en) 2007-10-01 2015-03-31 Bristol Myers Squibb Co Human antibodies that bind mesothelin, and uses thereof
US8034905B2 (en) 2007-11-09 2011-10-11 Affitech Research, AS Anti-VEGF antibody compositions and methods
CL2008003526A1 (en) 2007-11-30 2010-01-11 Medarex Inc Antibody-associated molecule conjugate comprising a human monoclonal anti human b7-h4 / 08e / b7x / b7s1 / bl-cam / b3 / leu-14 / lyb-8 antibody; composition comprising it; in vitro method of inhibition of tumor cell expressing b7-h4 / 08e / b7x / b7s1 / bl-cam / b3 / leu-14 / lyb-8; and use to treat cancer.
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
US8414356B2 (en) 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8221480B2 (en) 2008-10-31 2012-07-17 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8709411B2 (en) 2008-12-05 2014-04-29 Novo Nordisk A/S Combination therapy to enhance NK cell mediated cytotoxicity
TWI686405B (en) 2008-12-09 2020-03-01 建南德克公司 Anti-pd-l1 antibodies and their use to enhance t-cell function
AU2010289677B2 (en) 2009-09-03 2014-07-31 Merck Sharp & Dohme Llc Anti-GITR antibodies
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
EP2558498B1 (en) 2010-04-13 2016-10-12 Celldex Therapeutics, Inc. Antibodies that bind human cd27 and uses thereof
TWI535716B (en) 2010-05-31 2016-06-01 Ono Pharmaceutical Co Purine ketone derivatives
EA035033B1 (en) 2010-11-22 2020-04-20 Иннейт Фарма Са Method for treatment of hematological pre-malignancy or hematological malignancy
MX360254B (en) 2011-03-10 2018-10-26 Pfizer Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer.
JP6342325B2 (en) 2011-05-25 2018-06-13 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Anti-KIR antibodies for the treatment of inflammatory disorders
US20160206608A1 (en) 2011-08-02 2016-07-21 Pfizer Inc. Crizotinib for use in the treatment of cancer
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
US9041556B2 (en) 2011-10-20 2015-05-26 Apple Inc. Method for locating a vehicle
SG11201401386XA (en) 2011-11-09 2014-10-30 Bristol Myers Squibb Co Treatment of hematologic malignancies with an anti-cxcr4 antibody
US10864271B2 (en) * 2012-02-15 2020-12-15 Rutgers, The State University Of New Jersey Combination therapy using riluzole to enhance tumor sensitivity to ionizing radiation
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
BR112014028826A8 (en) 2012-05-15 2021-07-20 Bristol Myers Squibb Co monoclonal antibodies, use of anti-pd1, anti-pd-1 and anti-ctla-4 antibodies in immunotherapy and cancer treatment, as well as kits and individual selection process for treatment with anti-pd-1 antibody
KR101566538B1 (en) 2012-06-08 2015-11-05 국립암센터 Novel epitope for switching to Th17 cell and use thereof
WO2013192610A2 (en) * 2012-06-23 2013-12-27 Fox Chase Chemical Diversity Center, Inc. Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
PL2904011T3 (en) 2012-10-02 2018-01-31 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
AR097306A1 (en) 2013-08-20 2016-03-02 Merck Sharp & Dohme MODULATION OF TUMOR IMMUNITY
TW201605896A (en) 2013-08-30 2016-02-16 安美基股份有限公司 GITR antigen binding proteins
ES2728578T3 (en) 2013-09-20 2019-10-25 Bristol Myers Squibb Co Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
TWI660739B (en) 2013-10-25 2019-06-01 製藥公司 Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
NZ726513A (en) 2014-05-28 2023-07-28 Memorial Sloan Kettering Cancer Center Anti-gitr antibodies and methods of use thereof
SG11201700207WA (en) * 2014-07-11 2017-02-27 Genentech Inc Anti-pd-l1 antibodies and diagnostic uses thereof
US20160073759A1 (en) * 2014-09-15 2016-03-17 Beauty Solutions Agency Inc. Nail covering
US11236139B2 (en) * 2014-11-05 2022-02-01 The Regents Of The University Of California Combination immunotherapy
ES2843324T3 (en) * 2014-11-18 2021-07-16 Maximum Fidelity Surgical Simulations Llc Reconstitution of the post-mortem circulation
US20160140879A1 (en) * 2014-11-19 2016-05-19 David Hananel Anatomically correct movement or deformation of simulated bodily structures
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
JP6700293B2 (en) * 2015-03-03 2020-05-27 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． Riluzole prodrugs and their use
MY188749A (en) 2015-04-17 2021-12-28 Bristol Myers Squibb Co Compositions comprising a combination of nivolumab and ipilimumab
TW201725044A (en) 2015-10-01 2017-07-16 基利科學股份有限公司 Combination of a BTK inhibitor and a checkpoint inhibitor for treating cancers
RS62935B1 (en) * 2016-05-20 2022-03-31 Biohaven Therapeutics Ltd Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers

Also Published As

Publication number Publication date
ES2905823T3 (en) 2022-04-12
SI3458053T1 (en) 2022-04-29
US20190290619A1 (en) 2019-09-26
KR102369735B1 (en) 2022-03-02
PT3458053T (en) 2022-02-01
EP4019019B1 (en) 2024-02-07
EP4019019A1 (en) 2022-06-29
KR102525527B1 (en) 2023-04-24
US11400155B2 (en) 2022-08-02
WO2017201502A1 (en) 2017-11-23
IL262849A (en) 2018-12-31
CN115350263A (en) 2022-11-18
EP3458053A1 (en) 2019-03-27
IL292302B2 (en) 2023-10-01
JP2019516711A (en) 2019-06-20
PH12018502409A1 (en) 2019-04-08
EP3458053B1 (en) 2021-12-08
KR20220029772A (en) 2022-03-08
JP2022191256A (en) 2022-12-27
CY1124999T1 (en) 2023-01-05
CN109890387B (en) 2022-06-14
CN109890387A (en) 2019-06-14
WO2017201501A1 (en) 2017-11-23
EA201892587A1 (en) 2019-04-30
HRP20220237T1 (en) 2022-04-29
ZA201807398B (en) 2020-05-27
EP3458054B1 (en) 2022-02-23
IL292302B1 (en) 2023-06-01
AU2021221560A1 (en) 2021-09-16
KR20190009334A (en) 2019-01-28
US20190175731A1 (en) 2019-06-13
EP3458054A1 (en) 2019-03-27
JP7169195B2 (en) 2022-11-10
MX2022010377A (en) 2022-09-21
ES2912131T3 (en) 2022-05-24
PL3458053T3 (en) 2022-04-25
AU2021221560B2 (en) 2023-10-26
AU2017266951B2 (en) 2021-05-27
IL262849B (en) 2022-05-01
US20230310595A1 (en) 2023-10-05
DK3458053T3 (en) 2022-02-21
LT3458053T (en) 2022-02-25
EP3458053A4 (en) 2019-11-20
EP3458054A4 (en) 2019-10-02
JP7224186B2 (en) 2023-02-17
RS62935B1 (en) 2022-03-31
HUE058184T2 (en) 2022-07-28
JP2019516712A (en) 2019-06-20
JP2023012508A (en) 2023-01-25
IL292302A (en) 2022-06-01
MX2018013868A (en) 2019-02-21
CA3025019A1 (en) 2017-11-23
AU2017266951A1 (en) 2018-11-22
BR112018073781A2 (en) 2019-02-26

Similar Documents

Publication Publication Date Title
SG11201809669RA (en) Use of glutamate modulating agents with immunotherapies to treat cancer
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201806624XA (en) Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201901531TA (en) Regulation of gene expression using engineered nucleases
SG11201808990QA (en) Compositions for topical application of compounds
SG11201809554VA (en) Methods of treating skin cancer by administering a pd-1 inhibitor
SG11201807421TA (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201804765UA (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201901364VA (en) Engineered target specific nucleases
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201803983UA (en) Transformable tagging compositions, methods, and processes incorporating same
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201909011PA (en) Niraparib compositions
SG11201908478SA (en) Sterilisation method
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11202000145XA (en) Methods and systems for conditionally regulating gene expression
SG11202000055PA (en) Antibodies that modulate a biological activity expressed by a cell
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1